Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00044863 | Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma | PHASE2 | COMPLETED | 250 | — | — | Aug 1, 2002 | Dec 1, 2005 | Feb 23, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Patients with metastatic EGFR-positive colorectal carcinoma |
| Name | Type | Description |
|---|---|---|
| Erbitux (Cetuximab) | BIOLOGICAL | 400 mg/m2 initial dose, 250 mg/m2 weekly |
Inclusion Criteria: * Provided signed written informed consent. * Histologically- or pathologically- confirmed metastatic colorectal carcinoma; * Documented progressive disease after receiving either: 1. at least two chemotherapy regimens for metastatic disease or 2. adjuvant therapy plus one ...